Therefore, the difference in cytotoxicity against tumor organoids between olaparib (IC50 = 85 μM) and compound 4 (IC50 = 251 μM) is consistent with their respective potencies against PARP1-HPF1 complex. This evidence concerns the gene HPF1 and neoplasm.